Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F16%3A10324614" target="_blank" >RIV/00216208:11110/16:10324614 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/16:10324614
Result on the web
<a href="http://dx.doi.org/10.3233/CBM-160617" target="_blank" >http://dx.doi.org/10.3233/CBM-160617</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3233/CBM-160617" target="_blank" >10.3233/CBM-160617</a>
Alternative languages
Result language
angličtina
Original language name
Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis
Original language description
INTRODUCTION: We analyzed concentrations of osteopontin (OPN) in patients with pancreatic ductal adenocarcinoma (PDAC) in order to determine firstly whether it is useful to distinguish between PDAC patients and those with chronic non-hereditary pancreatitis (CP) and type 2 diabetes mellitus (T2DM), and secondly whether OPN concentrations depend on the PDAC stage. METHODS: Groups consisting of 64 patients with PDAC, 71 with CP, 67 with T2DM and 48 healthy controls (CON) were enrolled in the study. Controls were compared with regard to levels of OPN, oxidative stress markers, conventional tumor markers and other biochemical parameters. RESULTS: Levels of OPN were higher in patients with PDAC compared with CP patients (P< 0.001), T2DM (P< 0.001) and CON (P< 0.001). There were increased OPN levels in CP patients in comparison with T2DM (P< 0.001) and CON (P< 0.001). Patients with PDAC in stage IV had higher OPN levels than PDAC patients in stage III (P< 0.01). There was no difference in OPN levels of PDAC patients in stage III compared to patients in stage II. CONCLUSION: Our pilot study demonstrates the usefulness of estimating OPN levels to differentiate between pancreatic cancer and chronic pancreatitis. Higher OPN levels over 102 ng/ml could be a potential diagnostic biomarker for pancreatic cancer.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/FR-TI3%2F666" target="_blank" >FR-TI3/666: Identification of novel biomarkers panels in selected malignancies</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Biomarkers
ISSN
1574-0153
e-ISSN
—
Volume of the periodical
17
Issue of the periodical within the volume
1
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
11
Pages from-to
55-65
UT code for WoS article
000381114300008
EID of the result in the Scopus database
2-s2.0-84978518645